HighTide Therapeutics, Inc. (HKG:2511)
Hong Kong · Delayed Price · Currency is HKD 2.600
+0.100 (4.00%)
Jul 31, 2026, 2:42 PM HKT
HighTide Therapeutics Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 232.39 | 310.75 | 608.21 | 412.34 | 765.29 |
Short-Term Investments | 93.63 | 0.18 | 0.68 | 428.26 | 0.5 |
Trading Asset Securities | 176.81 | 179.77 | 127.49 | - | - |
Cash & Short-Term Investments | 502.83 | 490.7 | 736.38 | 840.6 | 765.79 |
Cash Growth | 2.47% | -33.36% | -12.40% | 9.77% | - |
Other Receivables | 15 | 0.86 | 7.35 | 0.47 | 0.28 |
Receivables | 15 | 0.86 | 7.35 | 0.47 | 0.28 |
Other Current Assets | 14.36 | 21.81 | 35.02 | 9.95 | 9.12 |
Total Current Assets | 532.19 | 513.37 | 778.75 | 851.02 | 775.18 |
Property, Plant & Equipment | 17.57 | 23.89 | 14.98 | 4.81 | 3.45 |
Long-Term Investments | - | 21.09 | - | - | - |
Other Long-Term Assets | 1.58 | 1.58 | 1.3 | - | - |
Total Assets | 551.34 | 559.93 | 795.04 | 855.82 | 778.63 |
Liabilities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 50.89 | 51.47 | 30.51 | 21.7 | 6.09 |
Accrued Expenses | 8.23 | 5.34 | 40.68 | 23.55 | 14.75 |
Short-Term Debt | 32.5 | 46.93 | 3.5 | 8.15 | 7 |
Current Portion of Long-Term Debt | - | - | - | 1,260 | - |
Current Portion of Leases | 6.19 | 5.49 | 2.47 | 1.11 | 0.25 |
Current Income Taxes Payable | 0.27 | 0.3 | 0.38 | 0.31 | 0.23 |
Current Unearned Revenue | - | - | 1.4 | 4.64 | - |
Other Current Liabilities | 0.21 | 0.42 | 0.87 | 0.24 | 0.21 |
Total Current Liabilities | 98.29 | 109.95 | 79.81 | 1,320 | 28.53 |
Long-Term Debt | 77.5 | 9.96 | - | - | 1,006 |
Long-Term Leases | 10.67 | 15.53 | 10.46 | 1.51 | 0.9 |
Long-Term Unearned Revenue | 0.21 | 0.33 | 1.99 | 5.12 | 15.56 |
Total Liabilities | 186.67 | 135.76 | 92.26 | 1,326 | 1,051 |
Shareholders' Equity
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.41 | 0.36 | 0.36 | 0.03 | 0.03 |
Additional Paid-In Capital | 2,423 | 2,316 | 2,316 | 30.61 | 30.61 |
Retained Earnings | -2,323 | -2,078 | -1,696 | -757.01 | -566.77 |
Treasury Stock | -0.04 | -0.04 | -0.04 | -0.01 | -0 |
Comprehensive Income & Other | 206.97 | 186.35 | 83.17 | 3.12 | 11.14 |
Total Common Equity | 307.01 | 424.17 | 702.77 | -723.26 | -524.99 |
Minority Interest | 57.66 | - | - | - | - |
Shareholders' Equity | 364.67 | 424.17 | 702.77 | -470.53 | -272.26 |
Total Liabilities & Equity | 551.34 | 559.93 | 795.04 | 855.82 | 778.63 |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 126.87 | 77.91 | 16.43 | 1,271 | 1,014 |
Net Cash (Debt) | 375.96 | 412.8 | 719.94 | -430.19 | -248.27 |
Net Cash Growth | -8.92% | -42.66% | - | - | - |
Net Cash Per Share | 0.78 | 0.91 | 2.77 | -1.69 | -5.91 |
Filing Date Shares Outstanding | 571.33 | 514.77 | 514.77 | 40.35 | 42.04 |
Total Common Shares Outstanding | 571.33 | 514.77 | 514.77 | 40.35 | 42.04 |
Working Capital | 433.9 | 403.43 | 698.94 | -468.7 | 746.65 |
Book Value Per Share | 0.54 | 0.82 | 1.37 | -17.92 | -12.49 |
Tangible Book Value | 307.01 | 424.17 | 702.77 | -723.26 | -524.99 |
Tangible Book Value Per Share | 0.54 | 0.82 | 1.37 | -17.92 | -12.49 |
Machinery | 4.11 | 4.53 | 6.09 | 5.29 | 5.11 |
Leasehold Improvements | 4.48 | 4.44 | 0.27 | 0.27 | 0.27 |